Death and disability from warfarin-associated intracranial and extracranial hemorrhages
- PMID: 17679129
- PMCID: PMC3534961
- DOI: 10.1016/j.amjmed.2006.07.034
Death and disability from warfarin-associated intracranial and extracranial hemorrhages
Abstract
Objectives: Little is known about the outcomes of patients who have hemorrhagic complications while receiving warfarin therapy. We examined the rates of death and disability resulting from warfarin-associated intracranial and extracranial hemorrhages in a large cohort of patients with atrial fibrillation.
Methods: We assembled a cohort of 13,559 adults with nonvalvular atrial fibrillation and identified patients hospitalized for warfarin-associated intracranial and major extracranial hemorrhage. Data on functional disability at discharge and 30-day mortality were obtained from a review of medical charts and state death certificates. The relative odds of 30-day mortality by hemorrhage type were calculated using multivariable logistic regression.
Results: We identified 72 intracranial and 98 major extracranial hemorrhages occurring in more than 15,300 person-years of warfarin exposure. At hospital discharge, 76% of patients with intracranial hemorrhage had severe disability or died, compared with only 3% of those with major extracranial hemorrhage. Of the 40 deaths from warfarin-associated hemorrhage that occurred within 30 days, 35 (88%) were from intracranial hemorrhage. Compared with extracranial hemorrhages, intracranial events were strongly associated with 30-day mortality (odds ratio 20.8 [95% confidence interval, 6.0-72]) even after adjusting for age, sex, anticoagulation intensity on admission, and other coexisting illnesses.
Conclusions: Among anticoagulated patients with atrial fibrillation, intracranial hemorrhages caused approximately 90% of the deaths from warfarin-associated hemorrhage and the majority of disability among survivors. When considering anticoagulation, patients and clinicians need to weigh the risk of intracranial hemorrhage far more than the risk of all major hemorrhages.
Figures


Similar articles
-
Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?JAMA. 2003 Nov 26;290(20):2685-92. doi: 10.1001/jama.290.20.2685. JAMA. 2003. PMID: 14645310
-
Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study.J Am Geriatr Soc. 2006 Aug;54(8):1231-6. doi: 10.1111/j.1532-5415.2006.00828.x. J Am Geriatr Soc. 2006. PMID: 16913990 Free PMC article.
-
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.Circulation. 2015 Jan 13;131(2):157-64. doi: 10.1161/CIRCULATIONAHA.114.012061. Epub 2014 Oct 30. Circulation. 2015. PMID: 25359164
-
Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses.Stroke. 1995 Aug;26(8):1471-7. doi: 10.1161/01.str.26.8.1471. Stroke. 1995. PMID: 7631356 Review.
-
Treasure to the mother and threat to the fetus: case report of warfarin-associated fetal intracranial hemorrhage and review of literature.J Int Med Res. 2023 Aug;51(8):3000605231192773. doi: 10.1177/03000605231192773. J Int Med Res. 2023. PMID: 37572075 Free PMC article. Review.
Cited by
-
Antithrombotic management of atrial fibrillation in the elderly.Med Clin North Am. 2015 Mar;99(2):417-30. doi: 10.1016/j.mcna.2014.11.012. Epub 2015 Jan 10. Med Clin North Am. 2015. PMID: 25700592 Free PMC article. Review.
-
Effect of atrial fibrillation in Asian patients undergoing percutaneous coronary intervention with drug-eluting stents for stable coronary artery disease: Results from a Korean nationwide study.Medicine (Baltimore). 2018 Nov;97(48):e13488. doi: 10.1097/MD.0000000000013488. Medicine (Baltimore). 2018. PMID: 30508978 Free PMC article.
-
Effect of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk.J Korean Neurosurg Soc. 2014 Feb;55(2):69-72. doi: 10.3340/jkns.2014.55.2.69. Epub 2014 Feb 28. J Korean Neurosurg Soc. 2014. PMID: 24653798 Free PMC article.
-
Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update.J Stroke. 2017 Jan;19(1):3-10. doi: 10.5853/jos.2016.00864. Epub 2017 Jan 31. J Stroke. 2017. PMID: 28178408 Free PMC article. Review.
-
The net clinical benefit of warfarin anticoagulation in atrial fibrillation.Ann Intern Med. 2009 Sep 1;151(5):297-305. doi: 10.7326/0003-4819-151-5-200909010-00003. Ann Intern Med. 2009. PMID: 19721017 Free PMC article.
References
-
- Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988. - PubMed
-
- Atrial Fibrillation Investigators Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–1457. - PubMed
-
- European Atrial Fibrillation Trial Study Group Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995;333:5–10. - PubMed
-
- Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019–1026. - PubMed
-
- Gage BF, Boechler M, Doggette AL, et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke. 2000;31:822–827. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical